keyword
MENU ▼
Read by QxMD icon Read
search

Oxaliplatin

keyword
https://www.readbyqxmd.com/read/28537875/n-myc-downstream-regulated-gene-1-promotes-oxaliplatin-triggered-apoptosis-in-colorectal-cancer-cells-via-enhancing-the-ubiquitination-of-bcl-2
#1
Xiao Yang, Fan Zhu, Chaoran Yu, Jiaoyang Lu, Luyang Zhang, Yanfeng Lv, Jing Sun, Minhua Zheng
N-myc downstream-regulated gene1 (NDRG1) has been identified as a potent tumor suppressor gene. The molecular mechanisms of anti-tumor activity of NDRG1 involve its suppressive effects on a variety of tumorigenic signaling pathways. The purpose of this study was to investigate the role of NDRG1 in the apoptosis of colorectal cancer (CRC) cells. We first collected the clinical data of locally advanced rectal cancer (LARC) patients receiving oxaliplatin-based neoadjuvant chemotherapy in our medical center. Correlation analysis revealed that NDRG1 positively associated with the downstaging rates and prognosis of patients...
May 9, 2017: Oncotarget
https://www.readbyqxmd.com/read/28535657/-safety-and-efficacy-of-infusional-fluorouracil-leucovorin-oxaliplatin-and-irinotecan-folfoxiri-in-chinese-patients-with-advanced-colorectal-cancer
#2
Y Song, W W Li, J Huang
Objective: To establish the maximum tolerated dose (MTD) of 5-fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI), and to evaluate the safety and efficacy in Chinese patients with advanced colorectal cancer. Methods: Patients were treated with a regimen consisting of infusional 5-fluorouracil (2 400 mg/m(2) on day 1), leucovorin (200 mg/m(2) on day 1), oxaliplatin (85 mg/m(2) on day 1), and irinotecan (at doses from 150 to 180 mg/m(2) on day 8) according to the dose-escalation schema. Treatment was repeated every 14 days...
May 23, 2017: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/28535648/-effect-of-%C3%AE-40p53-isoform-on-enhancing-the-pro-apoptotic-function-of-p53-in-tumor-cells
#3
B S Wang, H W Zhao, L X Qiao, J Q Shan, Q S Hou, D X Chen, H L Guo
Objective: To investigate the effect of Δ40p53, an alternative spliced isoform of p53 lacking the N-ter minus, on the pro-apoptotic function of p53. Methods: The wild-type p53 was ectopically expressed in HCT116-p53(-/-) (endogenous Δ40p53 expression), HCT116-p53(+ /+) (wild-type p53) and H1299 (p53-null) cells by adenoviral delivery, while Δ40p53 plasmid were transfected into these cells to overexpress Δ40p53. The levels of Δ40p53 and p53 mRNA were detected by reverse transcription-polymerase chain reaction (RT-PCR) and quantitative PCR...
May 23, 2017: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/28534337/-mir-145-inhibits-drug-resistance-to-oxaliplatin-in-colorectal-cancer-cells-through-regulating-g-protein-coupled-receptor-98
#4
Qiang Fu, Jing Cheng, Jindai Zhang, Yonglei Zhang, Xiaobing Chen, Jianguo Xie, Suxia Luo
OBJECTIVE: To predict and identify the target gene of miR-145, and to explore the underlying mechanism of the inhibition of miR-145 on drug resistance to Oxaliplatin (L-OHP) in human colorectal cancer cells. METHODS: L-OHP-resistant human colorectal cancer cell line (HCT116/L-OHP) was established in vitro by exposing to increased concentrations of L-OHP in cell culture medium. MiR-145-mimics and its negative control (NC-miRNA) were transfected into HCT116/L-OHP cells using liposome to establish HCT116/L-OHP(mimics) over-expressing miR-145 and HCT116/L-OHP(NC)...
May 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/28533490/is-folfoxiri-alone-or-combined-with-targeted-therapy-administered-as-first-line-treatment-a-reasonable-choice-for-most-patients-with-mcrc-systematic-review-and-network-meta-analysis
#5
Mingyi Zhou, Ping Yu, Dengue Bilibili Hernick Davin, Yanrong Li, Yuanhe Wang, Lingyu Fu, Jingdong Zhang
Whether the intensive administration of folinic acid, 5-fluorouracil, oxaliplatin and irinotecan (FOLFOXIRI) alone or combined with target therapy as first-line treatment could improve the prognosis of metastatic colorectal cancer (mCRC) patients is controversial. PubMed, the Cochrane Collaboration Central Register of Controlled Clinical Trials, Cochrane Systematic Reviews, ClinicalTrials.gov, the databases of conferences were queried to identify RCTs evaluating the efficacies and toxicities of intensive therapies used for first-line treatment of mCRC patients...
May 9, 2017: Oncotarget
https://www.readbyqxmd.com/read/28531891/dual-inhibition-of-egfr-and-vegf-in-heavily-pretreated-patients-with-metastatic-colorectal-cancer
#6
Finn Ole Larsen, Alice Markussen, Dorte Nielsen, Bonnie Colville-Ebeling, Lene B Riis, Benny V Jensen
OBJECTIVE: The aim of this study was to evaluate the efficacy and safety of combining irinotecan, bevacizumab, and cetuximab/panitumumab as a 4th-line treatment in patients with metastatic colorectal cancer. METHODS: All patients had KRAS wild-type metastatic colorectal cancer and had previously received fluoropyrimidine, oxaliplatin, irinotecan, and cetuximab/panitumumab in a 1st, 2nd, and 3rd line setting. Most patients had previously received bevacizumab as well...
May 23, 2017: Oncology
https://www.readbyqxmd.com/read/28528980/phospholipase-c-%C3%AE-1-negatively-regulates-autophagy-in-colorectal-cancer-cells
#7
Makoto Shimozawa, Sakiho Anzai, Reiko Satow, Kiyoko Fukami
Colorectal cancer (CRC) is one of the leading causes of cancer-related death worldwide. Kirsten rat sarcoma viral oncogene homolog (KRAS) is frequently mutated in CRC, and KRAS mutations promote cell motility, growth, and survival. We previously revealed that the expression of phospholipase C (PLC) δ1, one of the most basal PLCs, is down-regulated in colon adenocarcinoma, and that the KRAS signaling pathway suppresses PLCδ1 expression. Although recent studies revealed that KRAS mutations activate autophagy in cancer cells, a relation between PLCδ1 and autophagy remains unclear...
May 18, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/28525717/synthesis-and-biological-evaluation-of-novel-neuroprotective-pyridazine-derivatives-as-excitatory-amino-acid-transporter-2-eaat2-activators
#8
Alessia Chelini, Simone Brogi, Marco Paolino, Angela Di Capua, Andrea Cappelli, Gianluca Giorgi, Mersedeh Farzad, Lorenzo Di Cesare Mannelli, Laura Micheli, Carla Ghelardini, Maurizio Anzini
LDN-212320 (3) was found to be a potent EAAT2 activator at a translational level, restoring the normal clearance of glutamate and providing neuronal protection. Since the pharmacologic activation of EAAT2 represents a valuable strategy to relieve neuropathic pain, we synthesized novel activators (4a-f) of EAAT2. Among them 4f, analysed in comparison with compound 3 in different rat models of oxaliplatin-induced neuropathic pain, showed the better anti-hypersensitive profile being able to fully counteract the oxaliplatin-induced neuropathy...
May 19, 2017: Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/28516292/limax-test-improves-diagnosis-of-chemotherapy-associated-liver-injury-before-resection-of-colorectal-liver-metastases
#9
Johan F Lock, Tilman Westphal, Tom Rubin, Maciej Malinowski, Antje Schulz, Maximilian Jara, Jan Bednarsch, Martin Stockmann
BACKGROUND: Chemotherapy of colorectal liver metastases (CLMs) prior to liver resection implies the risk of chemotherapy-associated liver injury, leading to increased postoperative morbidity and mortality OBJECTIVE: The aim of this study was to evaluate the LiMAx (liver maximum capacity) test for diagnosis of chemotherapy-associated liver injury. METHODS: This was a retrospective analysis of patients with CLMs, prior to liver resection. We performed preoperative assessment of liver function using biochemical parameters and the LiMAx test...
May 17, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28515931/pharmaco-economic-analysis-of-adjuvant-chemotherapy-for-stage-ii-and-iii-colorectal-cancer
#10
Mina Iwai, Michio Kimura, Eiseki Usami, Tomoaki Yoshimura, Hitomi Teramachi
Comparison of the costs of capecitabine plus oxaliplatin (CapeOX) with that of FOLFOX6 (5-fluorouracil/leucovorin [LV] + oxaliplatin) as an adjuvant chemotherapy for stage II or III colorectal cancer has previously been reported. However, there are no reports comparing uracil and tegafur (UFT)/LV with capecitabine. Therefore, the current study compared the costs of adjuvant chemotherapy regimens including CapeOX, FOLFOX6, capecitabine and UFT/LV. The costs of chemotherapeutic drugs and for the prevention and treatment of adverse events were evaluated, as these account for the bulk of the treatment costs...
May 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28514739/cytoreductive-surgery-plus-hyperthermic-intraperitoneal-chemotherapy-improves-survival-for-peritoneal-carcinomatosis-from-colorectal-cancer-a-systematic-review-and-meta-analysis-of-current-evidence
#11
REVIEW
Chao-Qun Huang, Yao Min, Shu-Yi Wang, Xiao-Jun Yang, Yang Liu, Bin Xiong, Yutaka Yonemura, Yan Li
Objectives The therapeutic efficacy of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) is still under debate. This meta-analysis and systematic review of published literature on this comprehensive strategy aims to evaluate its efficacy on CRC patients with PC.Methods A systemic review with meta-analysis of published literatures on treatment of CRS plus HIPEC for patients with PC from CRC was performed...
April 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28513830/association-between-mutations-of-critical-pathway-genes-and-survival-outcomes-according-to-the-tumor-location-in-colorectal-cancer
#12
Dae-Won Lee, Sae-Won Han, Yongjun Cha, Jeong Mo Bae, Hwang-Phill Kim, Jaemyun Lyu, Hyojun Han, Hyoki Kim, Hoon Jang, Duhee Bang, Iksoo Huh, Taesung Park, Jae-Kyung Won, Seung-Yong Jeong, Kyu Joo Park, Gyeong Hoon Kang, Tae-You Kim
BACKGROUND: Colorectal cancer (CRC) develops through the alteration of several critical pathways. This study was aimed at evaluating the influence of critical pathways on survival outcomes for patients with CRC. METHODS: Targeted next-generation sequencing of 40 genes included in the 5 critical pathways of CRC (WNT, P53, RTK-RAS, phosphatidylinositol-4,5-bisphosphate 3-kinase [PI3K], and transforming growth factor β [TGF-β]) was performed for 516 patients with stage III or high-risk stage II CRC treated with surgery followed by adjuvant fluoropyrimidine and oxaliplatin chemotherapy...
May 17, 2017: Cancer
https://www.readbyqxmd.com/read/28511060/a-comparison-study-on-rnase-a-oligomerization-induced-by-cisplatin-carboplatin-and-oxaliplatin
#13
Delia Picone, Federica Donnarumma, Giarita Ferraro, Giovanni Gotte, Andrea Fagagnini, Giovanna Butera, Massimo Donadelli, Antonello Merlino
Cisplatin (CDDP) can form interprotein cross-links, leading to the formation of platinated oligomers. A dimer, a trimer and higher oligomers of bovine pancreatic ribonuclease (RNase A) obtained upon reaction with CDDP in 1:10 protein to metal ratio at 37°C have been previously characterized. Here, we verify the ability of carboplatin and oxaliplatin to induce RNase A oligomerization under the same experimental conditions. The amount of formed RNase A oligomers was compared with that obtained in the reaction of the protein with CDDP...
May 9, 2017: Journal of Inorganic Biochemistry
https://www.readbyqxmd.com/read/28510802/phase-i-ii-study-of-bi-weekly-xeliri-plus-bevacizumab-treatment-in-patients-with-metastatic-colorectal-cancer-resistant-to-oxaliplatin-based-first-line-chemotherapy
#14
Tsunekazu Mizushima, Mutsumi Fukunaga, Toshinori Sueda, Masataka Ikeda, Takeshi Kato, Ho Min Kim, Toshihiro Kudo, Kohei Murata, Junichi Nishimura, Taishi Hata, Chu Matsuda, Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori
PURPOSE: We aimed to determine the recommended dose for bi-weekly XELIRI plus bevacizumab for second-line chemotherapy and examined its safety and efficacy in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy. METHODS: Irinotecan and bevacizumab were administered as a continuous intravenous infusion on Day 1 at 150 mg/mm(2) and 5 mg/kg, respectively. Capecitabine was orally administered in two divided doses on Days 2-8...
May 16, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28507680/an-albumin-based-tumor-targeted-oxaliplatin-prodrug-with-distinctly-improved-anticancer-activity-in-vivo
#15
Josef Mayr, Petra Heffeter, Diana Groza, Luis Galvez, Gunda Koellensperger, Alexander Roller, Beatrix Alte, Melanie Haider, Walter Berger, Christian R Kowol, Bernhard K Keppler
The design of targeted platinum(iv) prodrugs is a very promising approach to enhance the low selectivity of platinum(ii) drugs towards cancerous tissue in order to reduce the impact on healthy tissue and, consequently, the often severe side-effects. Herein, we report a set of mono-functionalized cis- and oxaliplatin-based platinum(iv) complexes bearing a maleimide moiety, which allows selective binding to serum albumin in the bloodstream. This leads not only to a prolonged plasma half-life by avoidance of fast renal clearance, but also to preferential accumulation of the drug in the tumor tissue due to the EPR-effect...
March 1, 2017: Chemical Science
https://www.readbyqxmd.com/read/28506255/retrospective-study-of-nonmucinous-appendiceal-adenocarcinomas-role-of-systemic-chemotherapy-and-cytoreductive-surgery
#16
Marc Uemura, Wei Qiao, Keith Fournier, Jeffrey Morris, Paul Mansfield, Cathy Eng, Richard E Royal, Robert A Wolff, Kanwal Raghav, Gary N Mann, Michael J Overman
BACKGROUND: Mucinous appendiceal adenocarcinomas (AAs) are the most common histological subset of AAs. Nonmucinous AAs have been infrequently studied. We performed a single-center retrospective study to investigate this histological subtype. METHODS: We reviewed 172 patient records with nonmucinous AAs treated at MD Anderson Cancer Center from Jan, 1990 to Jun, 2015 and recorded patient demographics, tumor characteristics, treatment, and outcomes. Response rate (RR) was assessed semi-quantitatively (response/no response) according to the treating physician's findings...
May 15, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28505615/acute-disseminated-intravascular-coagulation-after-oxaliplatin-infusion
#17
Mark Waddle, Myra Irvin, Eva Gupta, Martin Gibbs, Tanya S Kakar, Nicole A Gannon, Jennifer R Arthurs, Deborah L Fischer, Sikander Ailawadhi
Oxaliplatin is one of the most commonly used drugs for patients with colorectal cancer. It has rarely been associated with disseminated intravascular coagulation (DIC) with only 3 previously reported cases. In all those instances, the patients had started receiving oxaliplatin, developed evidence of DIC during the course of planned treatment, and recovered with supportive care. We report a case of a 71-year-old man with colorectal cancer treated successfully with an oxaliplatin-based regimen who had disease relapse after 3 years...
May 16, 2017: Chemotherapy
https://www.readbyqxmd.com/read/28504409/multifunctional-liposomes-for-image-guided-intratumoral-chemo-phototherapy
#18
Dyego Miranda, Kevin Carter, Dandan Luo, Shuai Shao, Jumin Geng, Changning Li, Upendra Chitgupi, Steven G Turowski, Nasi Li, G Ekin Atilla-Gokcumen, Joseph A Spernyak, Jonathan F Lovell
Intratumoral (IT) drug injections reduce systemic toxicity, but delivered volumes and distribution can be inconsistent. To improve IT delivery paradigms, porphyrin-phospholipid (PoP) liposomes are passively loaded with three hydrophilic cargos: sulforhodamine B, a fluorophore; gadolinium-gadopentetic acid, a magnetic resonance (MR) agent; and oxaliplatin, a colorectal cancer chemotherapeutic. Liposome composition is optimized so that cargo is retained in serum and storage, but is released in less than 1 min with exposure to near infrared light...
May 15, 2017: Advanced Healthcare Materials
https://www.readbyqxmd.com/read/28504299/what-we-know-about-stage-ii-and-iii-colon-cancer-it-s-still-not-enough
#19
Alberto Puccini, Martin D Berger, Wu Zhang, Heinz-Josef Lenz
The introduction of oxaliplatin as adjuvant treatment for stage III colon cancer in 2004 has been the last practice changing progress in adjuvant treatment for patients with early colon cancer. Since then, many prognostic and predictive biomarkers have been studied, but only DNA mismatch repair status has been validated as having an important prognostic value. Accordingly, TNM and clinical-pathological patterns, such as pT4 lesions and lymph node sampling <12 nodes, are the main factors that guide physicians' choice regarding adjuvant treatment...
May 15, 2017: Targeted Oncology
https://www.readbyqxmd.com/read/28499428/clinical-benefit-of-adding-oxaliplatin-to-standard-neoadjuvant-chemoradiotherapy-in-locally-advanced-rectal-cancer-a-meta-analysis-oxaliplatin-in-neoadjuvant-treatment-for-rectal-cancer
#20
Francesca De Felice, Ilaria Benevento, Anna Lisa Magnante, Daniela Musio, Nadia Bulzonetti, Rossella Caiazzo, Vincenzo Tombolini
BACKGROUND: Neoadjuvant fluoropirimidine (5FU)-based chemoradiotherapy (CRT) has been considered the standard of care for locally advanced rectal cancer (LARC). Whether addition of oxaliplatin (OXP) will further improve clinical outcomes is still debated. We conducted a meta-analysis to evaluate the role of OXP in this patient population. METHODS: Literature searches were carried out in PubMed, Medline and Scopus databases. End points were overall survival (OS), disease free survival (DFS), local failure (LF) and distant failure (DF)...
May 12, 2017: BMC Cancer
keyword
keyword
73953
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"